Lobate-G

Name: Lobate-G Price Comparison: Uses, Dosage, Form & Side Effects
Creator: gmedication.com
Published: 2021-11-01T10:10:10+00:00

What was the prescribed dosage?

Here is the some steps to help you to save money on Lobate-G purchase.

Read drug prescription

What is Clobetasol (Lobate-G)
What is Gentamicin (Lobate-G)
Gentamicin (Lobate-G) side effects
Gentamicin (Lobate-G) dosing

Select the most affordable brand or generic drug
Frequently asked Questions

What other drugs will affect Gentamicin (Lobate-G)?
How should I take Gentamicin (Lobate-G)?
Who should not take Gentamicin (Lobate-G)?

Lobate-G reviews

Read drug prescription

consists of Clobetasol, Gentamicin.

Clobetasol (Lobate-G)

What is Clobetasol (Lobate-G)

Clobetasol propionate ointment contains the active compound Clobetasol (Lobate-G) propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol (Lobate-G), an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.
Clobetasol (Lobate-G) propionate ointment is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 grams per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended.
As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

Gentamicin (Lobate-G)

What is Gentamicin (Lobate-G)

Gentamicin (Lobate-G) is an antibiotic. It fights bacteria in the body.
Gentamicin (Lobate-G) is used to treat severe or serious bacterial infections.
Gentamicin (Lobate-G) may also be used for purposes other than those listed in Gentamicin (Lobate-G) guide.

Gentamicin (Lobate-G) side effects

If you experience any of the following serious side effects, stop taking Gentamicin (Lobate-G) and seek emergency medical attention:

an allergic reaction (shortness of breath; closing of the throat; hives; swelling of the lips, face, or tongue; rash; or fainting);
little or no urine;
decreased hearing or ringing in the ears;
dizziness, clumsiness, or unsteadiness;
numbness, skin tingling, muscle twitching, or seizures; or
severe watery diarrhea and abdominal cramps.

Other, less serious side effects may be more likely to occur. Continue to take Gentamicin (Lobate-G) and talk to your doctor if you experience

increased thirst;
loss of appetite;
nausea or vomiting;
a rash.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)

Gentamicin (Lobate-G) dosing

Usual Adult Dose for Bacteremia:

1.5 to 2 mg/kg loading dose, followed by 1 to 1.7 mg/kg IV or IM every 8 hours or 5 to 7 mg/kg IV every 24 hours
Duration of therapy: 14 days, depending on the site, nature, and severity of the bacteremia
Comments: Limiting the duration of Gentamicin therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Bacterial Endocarditis Prophylaxis:

1.5 mg/kg (maximum 120 mg) IV or IM once within 30 minutes of starting the procedure
Comments: For high risk patients, in addition to Gentamicin (Lobate-G), ampicillin 2 g is given IV or IM 30 minutes prior to the procedure, followed by ampicillin 1 g IV/IM or amoxicillin 1 g orally 6 hours later. In penicillin-allergic patients, vancomycin 1 g is infused IV 1 to 2 hours prior to the procedure.

Usual Adult Dose for Bacterial Infection:

1.5 to 2 mg/kg loading dose, followed by 1 to 1.7 mg/kg IV or IM every 8 hours, or 5 to 7 mg/kg IV every 24 hours
Duration of therapy: 7 to 21 days, depending on the nature and severity of the infection
Comments: Limiting the duration of Gentamicin therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Brucellosis:

2 mg/kg loading dose, followed by 1.7 mg/kg IV or IM every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: For the first 2 to 3 weeks of antibiotic therapy
Comments: Oral doxycycline or sulfamethoxazole/trimethoprim should be continued for at least 6 weeks.

Usual Adult Dose for Burns - External:

2 to 2.5 mg/kg loading dose, followed by 1.7 to 2 mg/kg IV every 8 hours
Duration of therapy: 10 to 14 days, depending on the nature and severity of the infection

Usual Adult Dose for Cystic Fibrosis:

5 to 10 mg/kg/day in 2 to 4 divided doses
Duration of therapy: Parenteral therapy should be continued for about 14 to 21 days, depending on the nature and severity of the infection and improvement of pulmonary function.

Usual Adult Dose for Endocarditis:

American Heart Association recommendations:
Native valve infections due to highly penicillin-susceptible viridans Group streptococci and S bovis (MIC <=0.12 mcg/mL): 3 mg/kg IV or IM once every 24 hours in combination with aqueous penicillin G sodium or ceftriaxone
Duration of therapy: 2 weeks; continue other antibiotic for 4 weeks
Native valve infections due to relatively penicillin-resistant S viridans and S bovis (MIC >0.12 mcg/mL and <=0.5 mcg/mL): 3 mg/kg IV or IM once every 24 hours in combination with aqueous penicillin G sodium or ceftriaxone
Duration of therapy: 2 weeks; continue other antibiotic for 4 weeks
Prosthetic valve infections due to S viridans and S bovis: 3 mg/kg IV or IM once every 24 hours in combination with aqueous penicillin G sodium or ceftriaxone
Duration of therapy: 2 weeks; continue other antibiotic for 6 weeks
Native valve infections due to staphylococci: 1.5 mg/kg IV or IM every 12 hours or 1 mg/kg every 8 hours, in combination with nafcillin, oxacillin, or cefazolin
Duration of therapy: 3 to 5 days; continue other antibiotic for 6 weeks
Prosthetic valve infections due to staphylococci: 1.5 mg/kg IV or IM every 12 hours or 1 mg/kg every 8 hours, in combination with nafcillin or oxacillin, plus rifampin, or vancomycin plus rifampin
Duration of therapy: 2 weeks; continue other antibiotics for at least 6 weeks
Native valve or prosthetic valve infections due to susceptible enterococci: 1 mg/kg IV or IM every 8 hours, in combination with ampicillin, aqueous penicillin G sodium, or vancomycin
Duration of therapy: 4 to 6 weeks; continue other antibiotic for 6 weeks
Native valve or prosthetic valve infections due to penicillin-resistant enterococci: 1 mg/kg IV or IM every 8 hours, in combination with ampicillin-sulbactam or vancomycin
Duration of therapy: 6 weeks
Comments: Refer to current published guidelines for detailed recommendations.

Usual Adult Dose for Endometritis:

2 mg/kg loading dose, followed by 1.5 mg/kg IV or IM every 8 hours
Duration of therapy: Parenteral therapy should be continued for at least 24 hours after the patient has remained afebrile, pain free, and the leukocyte count has normalized.

Usual Adult Dose for Febrile Neutropenia:

2 mg/kg loading dose, followed by 1.7 mg/kg IV every 8 hours
Duration of therapy: Once the patient is stable, afebrile for 24 hours, and the absolute neutrophil count is greater than 500/mm3, oral antibiotics may be substituted if antibiotic therapy is to be continued.

Usual Adult Dose for Intraabdominal Infection:

2 mg/kg loading dose, followed by 1.7 mg/kg IV every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: 14 days, depending on the nature and severity of the infection
Comments: Less toxic antibiotics may be substituted once the patient is stable for at least 48 hours.

Usual Adult Dose for Meningitis:

2 mg/kg loading dose, followed by 1.7 mg/kg IV or IM every 8 hours
Duration of therapy: Parenteral therapy should be continued for at least 1 week after the patient becomes afebrile and cerebrospinal fluid normalizes.

Usual Adult Dose for Osteomyelitis:

1.5 to 2 mg/kg loading dose, followed by 1 to 1.7 mg/kg IV or IM every 8 hours or 5 to 7 mg/kg IV every 24 hours
Duration of therapy: 4 to 6 weeks, depending on the nature and severity of the infection; chronic osteomyelitis may require an additional 1 to 2 months of oral antibiotics
Comments: Limiting the duration of Gentamicin therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Pelvic Inflammatory Disease:

2 mg/kg loading dose, followed by 1.5 mg/kg IV or IM every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: Parenteral therapy should be continued for at least 24 hours after clinical improvement and should be followed by oral doxycycline or clindamycin for a total 14 day course.

Usual Adult Dose for Peritonitis:

IV: 2 mg/kg loading dose, followed by 1.7 mg/kg IV every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: Therapy should be continued for about 14 days, depending on the nature and severity of the infection.
Comments: Limiting the duration of Gentamicin therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.
Intraperitoneally in CAPD patients: 0.6 to 0.75 mg/kg intraperitoneally once a day or 16 to 20 mg per every 2 L dialysate

Usual Adult Dose for Plague:

2 mg/kg loading dose, followed by 1.7 mg/kg IV or IM every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: Therapy should be continued for about 10 to 14 days, depending on the nature and severity of the infection.
Comments: Limiting the duration of Gentamicin (Lobate-G) therapy may help limit toxicity. Once the patient's condition improves, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Pneumonia:

2 mg/kg loading dose, followed by 1.7 mg/kg IV or IM every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: Therapy should be continued for 14 to 21 days, depending on the nature and severity of the infection.
Comments: Limiting the duration of Gentamicin therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Pyelonephritis:

2 mg/kg loading dose, followed by 1.7 mg/kg IV every 8 hours or 5 mg/kg IV every 24 hours
Duration of therapy: Therapy should be continued for about 7 to 14 days, depending on the nature and severity of the infection.
Comments: Limiting the duration of Gentamicin (Lobate-G) therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Skin or Soft Tissue Infection:

1.5 to 2 mg/kg loading dose, followed by 1 to 1.7 mg/kg IV or IM every 8 hours or 5 to 7 mg/kg IV every 24 hours
Duration of therapy: Therapy should be continued for at least 10 to 14 days, or until 3 days postacute inflammation, depending on the nature and severity of the infection; for severe infections, such as diabetic soft tissue infections, 14 to 21 days of therapy may be required
Comments: Limiting the duration of Gentamicin therapy may help limit toxicity. Once the patient is stable for at least 48 hours, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Adult Dose for Surgical Prophylaxis:

1.5 to 2 mg/kg (maximum 120 mg) IV or IM once at induction of anesthesia

Usual Adult Dose for Tularemia:

1.5 to 2 mg/kg loading dose, followed by 1 to 1.7 mg/kg IV or IM every 8 hours or 5 to 7 mg/kg IV every 24 hours
Duration of therapy: Therapy should be continued for about 10 to 14 days, depending on the nature and severity of the infection.
Comments: Once the patient's condition improves, less toxic IV or oral antibiotic therapy may be considered according to microbiology sensitivity data.

Usual Pediatric Dose for Bacterial Infection:

0 to 4 weeks, birthweight <1200 g: 2.5 mg/kg IV or IM every 18 to 24 hours
0 to 1 week, birthweight >=1200 g: 2.5 mg/kg IV or IM every 12 hours
1 to 4 weeks, birthweight 1200 to 2000 g: 2.5 mg/kg IV or IM every 8 to 12 hours
1 to 4 weeks, birthweight >=2000 g: 2.5 mg/kg IV or IM every 8 hours
>1 month: 1 to 2.5 mg/kg IV or IM every 8 hours

Usual Pediatric Dose for Bacterial Endocarditis Prophylaxis:

1.5 mg/kg IV or IM once within 30 minutes of starting the procedure
Comments: For high risk patients, in addition to Gentamicin, ampicillin 50 mg/kg (maximum 2 g) is given IV or IM 30 minutes prior to the procedure, followed by ampicillin 25 mg/kg IV/IM or amoxicillin 25 mg/kg orally 6 hours later. In penicillin-allergic patients, vancomycin 20 mg/kg IV is infused over 1 to 2 hours instead of ampicillin/amoxicillin.

Usual Pediatric Dose for Endocarditis:

AHA recommendations:
Native valve infections due to highly penicillin-susceptible viridans Group streptococci and S bovis (MIC <=0.12 mcg/mL): 3 mg/kg IV or IM once every 24 hours or 1 mg/kg every 8 hours in combination with aqueous penicillin G sodium or ceftriaxone
Duration of therapy: 2 weeks; continue other antibiotic for 4 weeks
Native valve infections due to relatively penicillin-resistant S viridans and S bovis (MIC >0.12 mcg/mL and <=0.5 mcg/mL): 3 mg/kg IV or IM once every 24 hours or 1 mg/kg every 8 hours in combination with aqueous penicillin G sodium or ceftriaxone
Duration of therapy: 2 weeks; continue other antibiotic for 4 weeks
Prosthetic valve infections due to S viridans and S bovis: 3 mg/kg IV or IM once every 24 hours or 1 mg/kg every 8 hours in combination with aqueous penicillin G sodium or ceftriaxone
Duration of therapy: 2 weeks; continue other antibiotic for 6 weeks
Native valve infections due to staphylococci: 1 mg/kg IV or IM every 8 hours, in combination with nafcillin, oxacillin, or cefazolin
Duration of therapy: 3 to 5 days; continue other antibiotic for 6 weeks
Prosthetic valve infections due to staphylococci: 1 mg/kg every 8 hours, in combination with nafcillin or oxacillin, plus rifampin, or vancomycin plus rifampin
Duration of therapy: 2 weeks; continue other antibiotics for at least 6 weeks
Native valve or prosthetic valve infections due to susceptible enterococci: 1 mg/kg IV or IM every 8 hours, in combination with ampicillin, aqueous penicillin G sodium, or vancomycin
Duration of therapy: 4 to 6 weeks; continue other antibiotic for 6 weeks
Native valve or prosthetic valve infections due to penicillin-resistant enterococci: 1 mg/kg IV or IM every 8 hours, in combination with ampicillin-sulbactam or vancomycin
Duration of therapy: 6 weeks
Comments: Refer to current published guidelines for detailed recommendations.

Usual Pediatric Dose for Surgical Prophylaxis:

2 mg/kg IV once at induction of anesthesia

Active ingredients: Clobetasol/Gentamicin

Select the most affordable brand or generic drug

Strength	Quantity	Price, USD	Country
Betanate-G
10 g		$0.13
Clobetamil-G
10 g		$0.13
CLOBETAMIL-G cream 15g		$0.13	Merck
Clobetamil-G Clobetasol propionate 0.05 %w/w, Gentamicin sulphate 0.1 %w/w. CRM / 10g		$0.13
Clobetasol/Gentamicin
Cortisol-G
20 g		$0.24
CORTISOL-G cream 20g		$0.24	Psycorem
Cortisol-G Clobetasol propionate 0.05 %w/w, Gentamicin 0.1 % w/w. CRM / 20g		$0.24
Cosvate-G
15 g		$0.18
Cosvate-G Clobetasol Pripionate 0.05%w/w, Gentamicin Sulphate 0.1%w/w OINT / 15g		$0.18
COSVATE-G cream 15g		$0.13	Adcock Ingram
Exel-G
10 g		$0.11
Exel-G Clobetasol propionate 0.05 %w/w, Gentamicin sulphate 0.1 %w/w. CRM / 10g		$0.11
EXEL-G cream 10g		$0.11	Ranbaxy (Consumer HC)
Tenovate-G
10 g		$0.13
Tenovate-G Clobetasol propionate 0.05 %w/w, Gentamycin (as sulphate)0.1 % w/w. CRM / 10g		$0.13
Tenovate-G Clobetasol propionate 0.05 %w/w, gentamycin sulphate 0.1 %w/w. CRM / 10g		$0.13
TENOVATE-G cream 10g		$0.13	GSK

References

Dailymed."Gentamicin sulfate: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
"Clobetasol". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
"Gentamicin". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Lobate-G - Frequently asked Questions

Can Lobate-G be stopped immediately or do I have to stop the consumption gradually to ween off?

In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.

It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.

What other drugs will affect Gentamicin (Lobate-G)?

Other drugs, especially those that affect the kidneys, can interact with Gentamicin (Lobate-G) resulting in dangerous side effects and/or decreased effectiveness. Do not take any other prescription or over-the-counter medicines, including vitamins, minerals, and herbal products, without first talking to your doctor during treatment with Gentamicin (Lobate-G).

How should I take Gentamicin (Lobate-G)?

If you are injecting Gentamicin (Lobate-G) at home, your healthcare provider will give you detailed instructions on how and where to inject the medication. If you do not understand these directions, do not attempt to inject the medication. Contact your healthcare provider for further instructions.

Do not use any Gentamicin (Lobate-G) that is discolored, has particles in it, or looks different from your previous doses. Throw away any unused Gentamicin (Lobate-G) after the amount of time determined by your pharmacist or doctor.

Adequate hydration is important during treatment with Gentamicin (Lobate-G). Fluids may be administered intravenously during treatment.

It is important that the medication be given on a regular schedule and for the entire amount of time prescribed by your doctor.

Gentamicin (Lobate-G) may cause damage to the kidneys and/or nerves. Kidney function and drug levels in the blood may be monitored with blood tests during treatment. Tell your doctor if you experience hearing loss, dizziness, numbness, skin tingling, muscle twitching, or seizures which may be signs of nerve damage.

Dispose of used needles and syringes in a puncture resistant container out of the reach of children.

Your healthcare provider will store Gentamicin (Lobate-G) as directed by the manufacturer or give you detailed storage instructions if you are storing the medication at home.

Who should not take Gentamicin (Lobate-G)?

Do not use Gentamicin (Lobate-G) without first talking to your doctor if you have

sulfite sensitivity;
kidney disease;
hearing loss or loss of balance due to ear problems;
Parkinson's disease; or
a neuromuscular disorder such as myasthenia gravis.

You may not be able to use Gentamicin (Lobate-G), or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Do not use Gentamicin (Lobate-G) without first talking to your doctor if you are pregnant or could become pregnant during treatment.

Do not use Gentamicin (Lobate-G) without first talking to your doctor if you are breast-feeding a baby.

Can Lobate-G be taken or consumed while pregnant?

Please visit your doctor for a recommendation as such case requires special attention.

Can Lobate-G be taken for nursing mothers or during breastfeeding?

Kindly explain your state and condition to your doctor and seek medical advice from an expert.

Reviews

Following the study conducted by gmedication.com on Lobate-G, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of Lobate-G. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.